TD Cowen on Syndax Pharmaceuticals (SNDX): 'We found the updates at ASH generally encouraging'
Tweet Send to a Friend
TD Cowen analyst Phil Nadeau reiterated a Buy rating on Syndax Pharmaceuticals (NASDAQ: SNDX)The analyst comments "Our Take: ASH Meeting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
